PTC Therapeutics Stock News

The FDA and the European Commission bestow Orphan Drug status to PTC Therapeutics' (PTCT) PTC923 for the treatment of hyperphenylalaninemia.

SOUTH PLAINFIELD, N.J., May 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC)

SOUTH PLAINFIELD, N.J., May 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conference: William Blair 41

SOUTH PLAINFIELD, N.J., May 17, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from the first study on the impact of caring for a child with the ultra-rare genetic di

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q1 2021 Results - Earnings Call Transcript

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -15.09% and 22.59%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

SOUTH PLAINFIELD, N.J., May 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2021.

PTC Therapeutics (PTCT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

SOUTH PLAINFIELD, N.J., April 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 fina

SOUTH PLAINFIELD, N.J., April 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate

SOUTH PLAINFIELD, N.J., April 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with typ

SOUTH PLAINFIELD, N.J., April 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals w

SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" fr

SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thurs

SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi�